• Yaghoubi M, Javanbakht M, Mashayekhi A, Hemami MR, Branagan-Harris M, Keeble TR. Cost-effectiveness analysis of Intravascular Temperature Management after cardiac arrest in England. medRxiv. 2021.
  • Moradi-Lakeh M, Yaghoubi M, Seitz P, Javanbakht M, Brock E. Cost-Effectiveness of Tisagenlecleucel in Paediatric Acute Lymphoblastic Leukaemia (pALL) and Adult Diffuse Large B-Cell Lymphoma (DLBCL) in Switzerland. Advances in Therapy. 2021;38(6):3427-43.
  • Javanbakht M, Moradi-Lakeh M, Mashayekhi A, Atkinson J. Continuous Monitoring of Respiratory Rate with Wearable Sensor in Patients Admitted to Hospital with Pneumonia Compared with Intermittent Nurse-Led Monitoring in the United Kingdom: A Cost-Utility Analysis. PharmacoEconomics-open. 2021:1-11.
  • Javanbakht M, Mashayekhi A, Branagan-Harris M, Moloney E. Economic Analysis of the CADScor System for Ruling Out Coronary Artery Disease in England. PharmacoEconomics-Open. 2021:1-13.
  • Javanbakht M, Mashayekhi A, Branagan-Harris M, Horvath P, Koenigsrainer A, Reymond MA, et al. Cost-effectiveness analysis of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with gastric cancer and peritoneal metastasis. European Journal of Surgical Oncology. 2021.
  • Javanbakht M, Mashayekhi A. PUK10 Cost–Utility Analysis of DyeVert Contrast Reduction Systems for Preventing Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary and/or Peripheral Angiography. Value in Health. 2021;24:S235-S6.
  • Bhattarai N, Price CI, McMeekin P, Javanbakht M, Vale L, Ford GA, et al. Cost-effectiveness of an enhanced Paramedic Acute Stroke Treatment Assessment (PASTA) during emergency stroke care: Economic results from a pragmatic cluster randomized trial. International Journal of Stroke. 2021:17474930211006302.
  • Ansaripour A, Roehrich K, Mashayekhi A, Wanjala M, Noel S, Hemami MR, et al. Budget Impact of the Vest™ High Frequency Chest Wall Oscillation System for Managing Airway Clearance in Patients with Complex Neurological Disorders: A US Healthcare Payers’ Perspective Analysis. PharmacoEconomics-Open. 2021:1-10.
  • Yaghoubi M, Mansell K, Vatanparast HH, Zeng W, Javanbakht M, Farag M. Patient level micro simulation model for evaluating the future potential cost effectiveness of pharmacy based interventions in the control and management of diabetes related complications in Canada. medRxiv. 2020.
  • Roze S, Isitt J, Smith-Palmer J, Javanbakht M, Lynch P. Long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring versus self-monitoring of blood glucose in patients with type 1 diabetes in the UK. Diabetes Care. 2020;43(10):2411-7.
  • Price CI, Shaw L, Islam S, Javanbakht M, Watkins A, McMeekin P, et al. Effect of an enhanced Paramedic acute stroke treatment assessment on thrombolysis delivery during emergency stroke care: a cluster randomized clinical trial. JAMA neurology. 2020;77(7):840-8.
  • Javanbakht M, Trevor M, Rezaei Hemami M, Rahimi K, Branagan-Harris M, Degener F, et al. Ticagrelor Removal by CytoSorb® in patients requiring emergent or urgent cardiac surgery: A UK-based cost-utility analysis. PharmacoEconomics-open. 2020;4(2):307-19.
  • Javanbakht M, Saleh H, Hemami MR, Branagan-Harris M, Boiano M. A corticosteroid-eluting sinus implant following endoscopic sinus surgery for chronic rhinosinusitis: a UK-based cost-effectiveness analysis. PharmacoEconomics-open. 2020:1-8.
  • Javanbakht M, Moloney E, Brazzelli M, Wallace S, Ternent L, Omar MI, et al. Economic evaluation of surgical treatments for women with stress urinary incontinence: a cost-utility and value of information analysis. BMJ open. 2020;10(6):e035555.
  • Javanbakht M, Moloney E, Brazzelli M, Wallace S, Omar MI, Monga A, et al. Surgical treatments for women with stress urinary incontinence: a systematic review of economic evidence. Systematic reviews. 2020;9(1):1-13.
  • Javanbakht M, Mashayekhi A, Trevor M, Rezaei Hemami M, L. Downey C, Branagan-Harris M, et al. Cost utility analysis of continuous and intermittent versus intermittent vital signs monitoring in patients admitted to surgical wards. Journal of medical economics. 2020;23(7):728-36.
  • Javanbakht M, Mashayekhi A, Trevor M, Branagan-Harris M, Atkinson J. Cost-utility analysis of normothermic liver perfusion with the OrganOx metra compared to static cold storage in the United Kingdom. Journal of Medical Economics. 2020;23(11):1284-92.
  • Javanbakht M, Mashayekhi A, Monga A, Atkinson J, Branagan-Harris M. Economic analysis of Electrical Muscle Stimulator with Multipath technology neuromuscular external electrical stimulation device for the treatment of stress urinary incontinence: a UK-based cost-utility analysis. JOURNAL OF MEDICAL ECONOMICS. 2020;23(9):1004-15.
  • Javanbakht M, Mashayekhi A, Monga A, Atkinson J, Branagan-Harris M. Economic analysis of Electrical Muscle Stimulator with Multipath technology for the treatment of stress urinary incontinence: a UK-based cost-utility analysis. Journal of Medical Economics. 2020;23(9):1004-15.
  • Javanbakht M, Mashayekhi A, Monga A, Atkinson J, Branagan-Harris M. Economic analysis of Innovo® neuromuscular external electrical stimulation device for the treatment of stress urinary incontinence: A UK-based cost-utility analysis. Journal of Medical Economics. 2020:1-.
  • Javanbakht M, Hemami MR, Mashayekhi A, Branagan-Harris M, Zaman A, Al-Najjar Y, et al. DyeVert™ PLUS EZ System for Preventing Contrast-Induced Acute Kidney Injury in Patients Undergoing Diagnostic Coronary Angiography and/or Percutaneous Coronary Intervention: A UK-Based Cost–Utility Analysis. PharmacoEconomics-open. 2020;4(3):459-72.
  • Price C, Shaw L, Islam S, Javanbakht M, Watkins A, McMeekin P, et al. The challenge of mimic conditions during pre-hospital stroke research: screening data from the Paramedic Acute Stroke Treatment Assessment (PASTA) trial. International Journal of Stroke. 2019;14(4 Supplement):50.
  • Javanbakht M, Trevor M, Rahimi K, Branagan-Harris M, Degener F, Blanco DA, et al. COST UTILITY ANALYSIS OF TICAGRELOR REMOVAL BY CYTOSORB® IN PATIENTS REQUIRING EMERGENT OR URGENT CARDIAC SURGERY IN THE UK. ISPOR Europe 2019. 2019.
  • Javanbakht M, Trevor M, Rahimi K, Branagan-Harris M, Degener F, Blanco D, et al. PCV112 COST UTILITY ANALYSIS OF TICAGRELOR REMOVAL BY CYTOSORB® IN PATIENTS REQUIRING EMERGENT OR URGENT CARDIAC SURGERY IN THE UK. Value in Health. 2019;22:S562.
  • Javanbakht M, Mashayekhi AM, Hemami MMR, Branagan-Harris M. High frequency chest wall oscillation system compared with manual chest wall physiotherapy for managing airway clearance in patients with complex neurological disorders: A UK-based cost-effectiveness analysis. European Respiratory Society; 2019.
  • Javanbakht M, Mashayekhi A, Montazeri M, Rezai Hemami M, Branagan-Harris M. The vest™ high-frequency chest wall oscillation system compared with manual chest wall physiotherapy for managing airway clearance in patients with complex neurological disorders: a UK-based cost-effectiveness analysis. The Open Pharmacoeconomics & Health Economics Journal. 2019;7(1).
  • Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1736-88.
  • Lozano R, Fullman N, Abate D, Abay SM, Abbafati C, Abbasi N, et al. Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):2091-138.
  • James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1789-858.